| scholarly article | Q13442814 |
| P2093 | author name string | Weilin Jin | |
| Juxiang Chen | |||
| Jiannong Zhao | |||
| Chaocai Zhang | |||
| Mingzhu Jin | |||
| P2860 | cites work | Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics | Q91984541 |
| An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma | Q92055634 | ||
| Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies | Q92109812 | ||
| A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity | Q92296473 | ||
| A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy | Q92427942 | ||
| Applications of patient-derived tumor xenograft models and tumor organoids | Q92476256 | ||
| Modeling Patient-Derived Glioblastoma with Cerebral Organoids | Q92505593 | ||
| Vascular regulation of antitumor immunity | Q92508400 | ||
| Individual brain organoids reproducibly form cell diversity of the human cerebral cortex | Q92548431 | ||
| A Xenotransplant Model of Human Brain Tumors in Wild-Type Mice | Q92602720 | ||
| Immunotherapy for Malignant Glioma: Current Status and Future Directions | Q92886948 | ||
| Modeling medulloblastoma in vivo and with human cerebellar organoids | Q93039110 | ||
| Cell stress in cortical organoids impairs molecular subtype specification | Q93040438 | ||
| Organoid Models of Glioblastoma to Study Brain Tumor Stem Cells | Q94564485 | ||
| Brain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the future | Q26753206 | ||
| Long-term culture of genome-stable bipotent stem cells from adult human liver | Q28254408 | ||
| The somatic genomic landscape of glioblastoma | Q28300185 | ||
| Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models | Q28468398 | ||
| Engineering Stem Cell Organoids | Q28973598 | ||
| Human cerebral organoids recapitulate gene expression programs of fetal neocortex development | Q28973614 | ||
| Cerebral organoids model human brain development and microcephaly | Q28973619 | ||
| A randomized trial of bevacizumab for newly diagnosed glioblastoma | Q30410163 | ||
| 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids | Q91622023 | ||
| Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy | Q91651395 | ||
| Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche | Q30495954 | ||
| Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | Q33561644 | ||
| Organoid models of human and mouse ductal pancreatic cancer | Q34456438 | ||
| Origin of the U87MG glioma cell line: Good news and bad news | Q34539119 | ||
| Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. | Q34554842 | ||
| Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme | Q34679133 | ||
| In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection | Q34758575 | ||
| Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma | Q35741739 | ||
| A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis | Q36026040 | ||
| Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. | Q36248008 | ||
| A Novel Mouse Model of Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells | Q36527913 | ||
| Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. | Q36831553 | ||
| Molecular and genetic properties of tumors associated with local immune cytolytic activity | Q36869059 | ||
| A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo | Q36917813 | ||
| Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice | Q37030008 | ||
| Instrumented cardiac microphysiological devices via multimaterial three-dimensional printing | Q37660675 | ||
| Microfluidics platform for measurement of volume changes in immobilized intestinal enteroids | Q37685939 | ||
| Cancer cell lines for drug discovery and development | Q38203358 | ||
| 3D Cell Printed Tissue Analogues: A New Platform for Theranostics | Q38637493 | ||
| Beyond organoids: In vitro vasculogenesis and angiogenesis using cells from mammals and zebrafish. | Q38659013 | ||
| Paving the Way Toward Complex Blood-Brain Barrier Models Using Pluripotent Stem Cells. | Q38731990 | ||
| Prospective derivation of a living organoid biobank of colorectal cancer patients. | Q38877277 | ||
| Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine | Q38885294 | ||
| Spatially gradated hydrogel platform as a 3D engineered tumor microenvironment. | Q38927445 | ||
| The bad seed gardener: Deubiquitinases in the cancer stem-cell signaling network and therapeutic resistance | Q39029913 | ||
| Organoid culture systems for prostate epithelial and cancer tissue. | Q39035547 | ||
| The Microenvironmental Landscape of Brain Tumors | Q39178065 | ||
| Reprogramming of the Tumor in the Hypoxic Niche: The Emerging Concept and Associated Therapeutic Strategies. | Q39365081 | ||
| Engineering CAR-T cells | Q39399864 | ||
| HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial | Q40234446 | ||
| Long-term, hormone-responsive organoid cultures of human endometrium in a chemically defined medium | Q41966840 | ||
| Genome sequencing of normal cells reveals developmental lineages and mutational processes | Q42997512 | ||
| Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. | Q45866445 | ||
| A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. | Q45946525 | ||
| Patient-derived xenografts undergo mouse-specific tumor evolution. | Q46291099 | ||
| Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial | Q47232913 | ||
| Organoids: An intermediate modeling platform in precision oncology. | Q47315105 | ||
| Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. | Q47553080 | ||
| Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma | Q47655431 | ||
| MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. | Q47768741 | ||
| BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance | Q48095662 | ||
| Human primary liver cancer-derived organoid cultures for disease modeling and drug screening | Q48317424 | ||
| A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. | Q48574942 | ||
| Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells | Q49013629 | ||
| SOX9-PDK1 axis is essential for glioma stem cell self-renewal and temozolomide resistance | Q49382495 | ||
| Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy | Q50327117 | ||
| Designer matrices for intestinal stem cell and organoid culture. | Q51099747 | ||
| One-step fabrication of an organ-on-a-chip with spatial heterogeneity using a 3D bioprinting technology. | Q51291550 | ||
| Brain tumour cells interconnect to a functional and resistant network. | Q52147171 | ||
| Glioblastoma Model Using Human Cerebral Organoids. | Q52431860 | ||
| Organoids in cancer research. | Q52564853 | ||
| Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. | Q52583527 | ||
| Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. | Q52615294 | ||
| Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. | Q53399373 | ||
| Ubiquitin-specific protease 22 acts as an oncoprotein to maintain glioma malignancy through deubiquitinating B cell-specific Moloney murine leukemia virus integration site 1 for stabilization. | Q55457011 | ||
| Genetically engineered cerebral organoids model brain tumor formation | Q57174300 | ||
| Spontaneous Glioblastoma Spheroid Infiltration of Early-Stage Cerebral Organoids Models Brain Tumor Invasion | Q59882535 | ||
| Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments | Q63407213 | ||
| Organoid Modeling of the Tumor Immune Microenvironment | Q64119748 | ||
| Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma | Q64267591 | ||
| Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. | Q64882923 | ||
| Cancer modeling meets human organoid technology | Q69497099 | ||
| Generation of human vascularized brain organoids | Q88145226 | ||
| CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response | Q89070233 | ||
| Chimeric Antigen Receptor Therapy | Q89419402 | ||
| Combining microenvironment normalization strategies to improve cancer immunotherapy | Q89517466 | ||
| Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids | Q89520878 | ||
| Organoids to study immune functions, immunological diseases and immunotherapy | Q89952131 | ||
| Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing | Q89983929 | ||
| Advancing insights into stem cell niche complexities with next-generation technologies | Q90382135 | ||
| Patient-Derived Glioma Models: From Patients to Dish to Animals | Q90419003 | ||
| Engineering of human brain organoids with a functional vascular-like system | Q90576467 | ||
| Organoids: A Platform Ready for Glioblastoma Precision Medicine? | Q90628270 | ||
| CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma | Q90796524 | ||
| Towards manufacturing of human organoids | Q90799537 | ||
| Blood vessel formation in cerebral organoids formed from human embryonic stem cells | Q90820015 | ||
| Mechanoimmunology: molecular-scale forces govern immune cell functions | Q90834353 | ||
| Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids | Q90903331 | ||
| Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors | Q90929525 | ||
| CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016 | Q91054612 | ||
| Microglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology | Q91165374 | ||
| A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization | Q91223444 | ||
| Three dimensional in vitro models of cancer: Bioprinting multilineage glioblastoma models | Q91285388 | ||
| Organoids - Preclinical Models of Human Disease | Q91379875 | ||
| Establishing Cerebral Organoids as Models of Human-Specific Brain Evolution | Q91421377 | ||
| Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas | Q91610482 | ||
| P433 | issue | 8 | |
| P921 | main subject | glioblastoma | Q282142 |
| organoid | Q11293125 | ||
| P304 | page(s) | 2242-2257 | |
| P577 | publication date | 2020-08-01 | |
| P1433 | published in | American Journal of Cancer Research | Q17511667 |
| P1476 | title | Organoid models of glioblastoma: advances, applications and challenges | |
| P478 | volume | 10 |
Search more.